Literature DB >> 10873364

Cell production rates in human tissues and tumours and their significance. Part II: clinical data.

D A Rew1, G D Wilson.   

Abstract

This paper reviews the available data for cell production rates of human tissues and tumours, measured in vivo using halogenated pyrimidine labelling and laser cytometry. The technique has now been widely evaluated, and we draw general inferences from the proliferative data over a broad range of tumour and tissue types. Estimates of the S-phase duration, the time taken for DNA synthesis in cycling cells, are consistent over a narrow range with a median value of around 10 hours, notwithstanding the constraints of the experimental and statistical technique, in normal tissues and tumours. This suggests that Ts values may be a species-specific constant. The more easily measured labelled S-phase fraction, or labelling index, shows much greater intra and intertumour variation within any one tumour class. It may thus be a surrogate for time dependent measurements to a first order approximation. The cell production rate, described by the potential doubling time (Tpot), is remarkably rapid in most tumours, a median value of the order of 5 days, and much faster than clinical volume doubling times for most lesions. The rapid cell production rates in normal tissues and tumours highlight the importance of cell loss in the growth and modelling of biological structures. Cell production rate measurements do not adequately describe the biological aggressiveness of tumours. They may be used to refine adjuvant strategies for radiotherapy and chemotherapy in experimental research. Dynamic halogenated pyrimidine labelling has provided unique and valuable insights into the living biology of human tissues and tumours. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873364     DOI: 10.1053/ejso.1999.0907

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  32 in total

1.  The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.

Authors:  E A Gaffney
Journal:  J Math Biol       Date:  2003-10-27       Impact factor: 2.259

2.  A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation.

Authors:  Igor Shuryak; Philip Hahnfeldt; Lynn Hlatky; Rainer K Sachs; David J Brenner
Journal:  Radiat Environ Biophys       Date:  2009-06-05       Impact factor: 1.925

3.  The distribution of cellular turnover in the human body.

Authors:  Ron Sender; Ron Milo
Journal:  Nat Med       Date:  2021-01-11       Impact factor: 53.440

4.  Optimal MRI interval for detection of asymptomatic recurrence in surgically treated early cervical cancer by use of a mathematical model.

Authors:  A Laios; K Gubbala; R Lampe; A Tolis
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

Review 5.  A role for Rtt109 in buffering gene-dosage imbalance during DNA replication.

Authors:  Yoav Voichek; Raz Bar-Ziv; Naama Barkai
Journal:  Nucleus       Date:  2016-07-03       Impact factor: 4.197

6.  Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability.

Authors:  Hatim Fakir; Lynn Hlatky; Huamin Li; Rainer Sachs
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

7.  Modeling progression in radiation-induced lung adenocarcinomas.

Authors:  Hatim Fakir; Werner Hofmann; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2010-01-08       Impact factor: 1.925

8.  Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.

Authors:  M Hedman; T Björk-Eriksson; O Brodin; I Toma-Dasu
Journal:  Br J Radiol       Date:  2013-03-11       Impact factor: 3.039

9.  The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status.

Authors:  M Derenzini; C Ceccarelli; D Santini; M Taffurelli; D Treré
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

10.  O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.

Authors:  A J Watson; M R Middleton; G McGown; M Thorncroft; M Ranson; P Hersey; G McArthur; I D Davis; D Thomson; J Beith; A Haydon; R Kefford; P Lorigan; P Mortimer; A Sabharwal; O Hayward; G P Margison
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.